Alloplex’s Abstract (3599) ‘Interleukin-10 and transforming growth factor-beta do not suppress tumor killing activity of PBMC-derived SUPLEXA cells’ has been accepted by AACR and is scheduled for presentation in a Poster session at the 2022 annual meeting in New Orleans, Louisiana.
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
The theme of this year’s meeting is “Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.” It reflects the American Association for Cancer Research’s ‘focus on the myriad of processes that contribute to cancer development and, in particular, how those processes vary from patient to patient depending on their environment, lifestyle, and germline genetics’.
Visit the AACR website: https://www.aacr.org/meeting/aacr-annual-meeting-2022/
View the meeting brochure: https://www.aacr.org/wp-content/uploads/2022/01/2103030T_22AM_CFA_pdf_11.pdf
Are you an analyst, member of the media, business development professional or investor who’d like to receive Alloplex announcements? Please email your contact details to firstname.lastname@example.org
(Subject: News request).